NovaBay Pharmaceuticals Inc
This page provides a comprehensive, data-driven snapshot of the NovaBay Pharmaceuticals Inc share listed on the ASE exchange. The data presented here is real and not based on assumptions. Since the data is refreshed on a daily or weekly basis, there may be a slight delay. On this page, you can view metrics such as market cap, day's high/low, 52-week high/low, the stock's P/E ratio, and other factors, and compare them with other stocks. While we do not claim that this data alone should dictate your financial decisions, it can certainly assist you in making them; the date of the last data refresh is displayed below the stock price. Explore NovaBay Pharmaceuticals Inc stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
NBY — Monthly Price History
Adjusted close price · Hover to see price & month
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Vertex Pharmaceuticals Incorporated | $451.63 | 26.79 | $114.63 B | — | — | 0.24% | $507.92 / $362.5 | $76.18 |
| 2. | Regeneron Pharmaceuticals, Inc. | $810.31 | 19.69 | $85.22 B | 0.44% | 10.23% | 13.81% | $859.34 / $541 | $295.71 |
| 3. | Moderna, Inc. | $140.33 | — | $58.11 B | — | -29.7% | -39.2% | $176.66 / $22.28 | $21.95 |
| 4. | Revolution Medicines, Inc. | $207.32 | — | $45.01 B | — | -57.28% | -54.06% | $224.31 / $39.17 | $8.28 |
| 5. | Royalty Pharma plc | $60.59 | 45.13 | $36.78 B | 2.96% | 8.21% | 12.25% | $64.38 / $34.08 | $11.22 |
| 6. | Alnylam Pharmaceuticals, Inc. | $260.1 | 44.07 | $35.61 B | — | 14.33% | 93.61% | $495.55 / $197.81 | $5.96 |
| 7. | Roivant Sciences Ltd. | $41.48 | — | $34.19 B | — | -21.06% | -6.12% | $37.97 / $12.54 | $6.28 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | -0.52 M | 0.52 M | 0 M | 0 M | 2.31 M | — |
| Operating Profit | -1.82 M | -1.17 M | -1.89 M | -2.7 M | -1.29 M | — |
| Net Profit | -26.6 M | -1.29 M | -1.92 M | 7.67 M | -1.21 M | — |
| EPS in Rs | -1 | -0.05 | -0.07 | 0.29 | -0.05 | -9.6 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 10.46 M | 14.4 M |
| Operating Profit | -7.58 M | -7.38 M | -4.1 M | -7.68 M |
| Net Profit | -22.14 M | -7.22 M | -9.64 M | -10.61 M |
| EPS in Rs | -0.83 | -0.27 | -0.36 | -0.4 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 9.04 M | 3.42 M | 9.03 M | 16.4 M |
| Total Liabilities | 32.21 M | 3.55 M | 5.72 M | 5.84 M |
| Equity | -23.18 M | -0.13 M | 3.31 M | 10.55 M |
| Current Assets | 8.68 M | 1.94 M | 7.15 M | 11.33 M |
| Current Liabilities | 1.14 M | 2.84 M | 4.28 M | 4.26 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -8.43 M | -7.5 M | -4.26 M | -6.65 M |
| Investing CF | — | 1.06 M | -0.02 M | -0.11 M |
| Financing CF | 4.62 M | 1.5 M | 1.91 M | 4.63 M |
| Free CF | -8.43 M | -7.5 M | -4.28 M | -6.77 M |
| Capex | — | -0.01 M | -0.02 M | -0.11 M |
5Y Margin & Growth History
Last 5 years of annual financial statement data.
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | -27.42% | — | — |
| Earnings Growth % | 25.07% | 9.13% | — | — |
| Profit Margin % | — | -92.2% | -73.65% | — |
| Operating Margin % | — | -39.23% | -53.32% | — |
| Gross Margin % | — | 58.19% | 54.02% | — |
| EBITDA Margin % | — | -39.17% | -49.97% | — |
Dividend & Split History
Latest dividend payments and stock split events.
Dividend History
| Ex Date | Dividend |
|---|---|
| 2025-09-30 | $4 |
Stock Splits
| Date | Split |
|---|---|
| 2026-02-23 | 1:0.2 |
| 2024-05-31 | 1:0.0285714 |
| 2022-11-16 | 1:0.0285714 |
Frequently Asked Questions — NovaBay Pharmaceuticals Inc
Will NovaBay Pharmaceuticals Inc stock hit $1 in 2026?
NovaBay Pharmaceuticals Inc (NBY) is currently trading at $0.87, with a 52-week range of $0.83 to $99.75. Reaching the $1 level would represent a 20% gain from the current price — a target many investors consider when evaluating near-term upside potential.
Whether NovaBay Pharmaceuticals Inc can reach $1 in 2026 depends on several factors: revenue and earnings growth trajectory, broader market conditions, sector sentiment within the Healthcare space, and any company-specific catalysts such as product launches, earnings beats, or strategic announcements.
Historically, NBY has delivered a -78.3% CAGR over the past 5 years, which suggests the stock has demonstrated meaningful long-term growth momentum. However, past performance does not guarantee future results, and short-term price movements can be influenced by macroeconomic shifts, interest rate changes, and investor sentiment. Use the NBY Stock Return Calculator on StockSifting to model different growth scenarios and see how various CAGR assumptions translate to potential price targets. This content is for informational purposes only and does not constitute financial advice.
Is NovaBay Pharmaceuticals Inc stock worth buying at $0.87?
Whether NovaBay Pharmaceuticals Inc (NBY) is worth buying at $0.87 depends on your investment goals, time horizon, and risk tolerance. Here is a breakdown of the key metrics investors typically evaluate:
Valuation: Valuation data is currently limited — check the full ratios section on StockSifting for the latest P/E, P/B, and EV/EBITDA figures.
Profitability & efficiency: NovaBay Pharmaceuticals Inc has a Return on Capital Employed (ROCE) of -96.1%, which reflects modest capital efficiency. Its Return on Equity (ROE) stands at -109.4%.
Financial health: The Debt-to-Equity ratio of -0.03 indicates a conservative balance sheet with more equity than debt, reducing financial risk.
Analyst view: Analyst estimates are not currently available for NBY. Always conduct your own due diligence and consider consulting a qualified financial advisor before making any investment decisions. Nothing on StockSifting constitutes financial advice.
What is the analyst price target for NovaBay Pharmaceuticals Inc (NBY) in 2026?
Analyst price target data for NovaBay Pharmaceuticals Inc (NBY) is not currently available on StockSifting. Analyst coverage and price targets are typically published by brokerage research desks for widely followed stocks, and are updated regularly after earnings results or major corporate events. Check back for the latest estimates, or explore NBY's financial ratios, historical returns, and fundamental data available on this page to form your own view.
How much can you earn by reinvesting NovaBay Pharmaceuticals Inc dividends?
Dividend reinvestment — commonly known as DRIP (Dividend Reinvestment Plan) — is a powerful wealth-building strategy where instead of receiving your dividend payouts as cash, the dividends are automatically used to purchase additional shares of NovaBay Pharmaceuticals Inc (NBY). Over time, this creates a compounding effect: more shares generate more dividends, which buy even more shares.
The key variables that determine your DRIP returns are: your initial investment amount, the number of years you stay invested, the dividend yield at the time of each reinvestment, and whether NovaBay Pharmaceuticals Inc grows or cuts its dividend over time. Market price appreciation of NBY also plays a significant role — rising share prices increase the value of your accumulated shares.
Use the NBY DRIP Calculator on StockSifting to enter your investment amount, start date, and contribution frequency — and see a year-by-year breakdown of shares accumulated, dividends earned, and total portfolio value. Past dividend payments are not a guarantee of future payouts. This is not financial advice.